Summary (tl;dr)

President Donald Trump signed an executive order on December 18, 2025, to reclassify marijuana from a Schedule I to a Schedule III controlled substance, marking a historic shift in federal drug policy. This move recognizes the medical value of cannabis and is expected to ease research and financial burdens on the legal cannabis industry.

Essential Background

Under the U.S. Controlled Substances Act of 1970, drugs are categorized into "schedules" based on their potential for abuse, accepted medical use, and safety. Marijuana has been classified as a Schedule I drug, alongside substances like heroin and LSD, implying it has no currently accepted medical use and a high potential for abuse. This classification has persisted despite many states legalizing cannabis for medical or recreational purposes. The Biden administration's Department of Health and Human Services (HHS) had previously recommended moving marijuana to Schedule III, following a scientific and medical evaluation in August 2023, but the process became mired in legal and administrative wrangling.

The Full Story

On Thursday, December 18, 2025, President Donald Trump signed an executive order in the Oval Office to expedite the reclassification of marijuana from Schedule I to Schedule III. This executive order directs the Attorney General to take the necessary steps to complete the rulemaking process for rescheduling marijuana. While this action does not federally legalize recreational cannabis, it acknowledges the plant's legitimate medical uses and moves it into a category with drugs like Tylenol with codeine, testosterone, and ketamine, which have a moderate to low potential for physical and psychological dependence. The order is also expected to allow a pilot program where Medicare beneficiaries could be reimbursed for certain CBD treatments.

Why It Matters

This reclassification is considered one of the most significant changes to U.S. drug policy in decades, with substantial implications for the cannabis industry, medical research, and public perception. For state-licensed cannabis businesses, it could significantly lower their federal tax burden by allowing them to deduct standard business expenses, a benefit previously denied under IRS Code section 280E due to marijuana's Schedule I status. The move is also anticipated to facilitate more scientific research into cannabis by easing restrictions associated with Schedule I drugs, potentially leading to expanded medical uses and new pharmaceutical products. Furthermore, it could encourage institutional investors to enter the cannabis space and potentially prompt more states to modernize their own cannabis policies. The recognition of marijuana's medical value at the federal level represents a shift from decades of stringent prohibition.

Geographic Location

• Oval Office, The White House, Washington, D.C., District of Columbia, United States (President Trump signed an executive order to reclassify marijuana)